Cancerous Growth: When Oncology Drug Prices Keep Increasing, Only Big Pharma Wins

December 20, 2018

In North Carolina, there were an estimated 55,130 new cases of cancer in 2018 alone. The estimated number of deaths is 20,380. The rest of the U.S. saw 1,735,350 new cancer cases this year, with an estimated $147 billion of the healthcare necessary for treatment going towards just oncology drugs alone.

It is difficult to fathom such numbers. The good news is that with the advancement of medical and pharmaceutical technology, cancer has slowly become more treatable. The bad news, however, is that the price tag associated with having cancer has bloated to incomprehensible numbers, and we must do our part in slowing the growth of the costs of oncology drugs. Insurers and Pharmacy Benefits Managers (PBMs) are there to help consumers by negotiating with drug companies to lower their prices, but pharmaceutical companies have exclusive rights that often allow them to avoid negotiations altogether and set exhorbitant prices.

Between 2006 and 2015, the average monthly oncology drug costs doubled from $7,103 to $15,535. More than that, people are spending double what they spend almost every 5 years. What cost $79,000 in 2013 now costs $150,000 in 2017, and that number is projected to grow by double in 2022. When drug prices are that high and continue to grow unchecked, nobody wins except for Big Pharma’s pockets.

When a pharmaceutical company launches a new drug, they have patent rights which allow them exclusive rights to price the drug however high they want. This creates a financial burden often too extreme for people who need it most. For example, a new breast cancer drug was released this year and the average cost was $13,886 per month.

Supposedly, as the patent expires, the price of the drug should go down as generics are able to come into the market. The theory behind patenting life-saving drugs is that since drug companies invest so much time and money in research, development, and testing before the drug is released to the public, they should have exclusive rights to sell their product for a period of time to recoup what they spent during development– and turn a profit to then use in the investment of the next drug. Then, with the passage of time and the introduction of generics, that drug will eventually become more affordable. That’s the theory.  

However, we are seeing drug companies raise prices exorbitantly in the time that they have exclusive rights. Take for example Gleevec, which launched in 2001 with a $26,000 a year price tag. By the time its patent expired, it cost $120,000 a year—even with the passage of time and the introduction of generics.

Gene therapies like CAR-T, which are closer than ever to curing cancer, will cost a patient almost one million dollars. Peter B. Bach, the Director of Memorial Sloan Kettering’s Center for Health and Policy Outcomes, says, “The one truth about cancer drugs is that prices are always higher than they were the year before. Now every time we get a new drug that costs more, it signals that you can get away with charging even more.” And it’s true. If these CAR-T drugs were used to treat just 40% of the people who die from cancer each year—about 250,000 people—the U.S. would see a spending increase on this one drug equivalent to $93 billion.

Now the questions remain: With out-of-control oncology drug prices, who can afford to treat cancer? How can we fix this broken system? How can the average consumer conceivably be able to afford six figures, or one million dollars, worth of treatment? Big Pharma is pricing necessary life-saving drugs at a premium that the average consumer simply cannot afford.

Organizations like Runaway Rx are actively fighting to keep people informed of Big Pharma’s deliberate attempts to keep people in the dark about their price gouging methods. In North Carolina, we at the NC Coalition for Fiscal Health are doing the same thing. We aim to keep North Carolinians informed about the truth behind their healthcare.

Have the sky-high costs of healthcare in our state impacted you and/or your family’s lives? Do you want to do something about it? Join the Coalition now to receive updates about new legislation and policies that will affect YOUR healthcare. Sign up now!

Action Needed

Tell your representative to say "no" to higher drug costs

We’ve told you about big Pharma’s brazen attempt to gut the last remaining protection for patients against runaway drug prices.

Now the most profitable industry in the world is quietly pushing a bill through the state legislature that would cripple pharmacy benefit managers (PBMs), which negotiate lower drug costs for North Carolinians.

We cannot let big pharma use the law to eliminate our only advocate in price negotiations.

Comment on This Article   

Post Your Comment

Please check your e-mail for a link to activate your account.

Related Articles

New Year, Same Price Hikes From Big Pharma
Round-up of Top Stories From The Latest Session
Rep. Pittman and the NFIB – Standing up for lower health care costs

Featured Articles

Cost of COVID-19: Pharma Giant Stock Price Soars on COVID-19 Vaccine News, but Will Big Profit Hopes Price Some Out?
BREAKING: Medicaid Transformation – and Millions in Taxpayer Savings – Approaches Finish Line
Cost of COVID-19: Telehealth is a life (and cost) saver
Cost of COVID-19: PBMs Advocate for Increased Access to Meds as COVID-19 Rages On
Cost of COVID-19: Blue Cross NC Waives Fees for COVID-19 Treatment
Cost of COVID-19: Steps you can take right now to save on health care costs